Stockscreener 앱 받기
1.14
0.00%
0.00
Pharmacyte Biotech Inc 주식(PMCB)의 최신 뉴스
IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING - Barchart.com
Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Increases By 382.4% - Defense World
PharmaCyte Biotech (OTCMKTS:PMCBD) Trading Up 3.8% – Here’s What Happened - Defense World
Malignant Ascites Pipeline 2025: Groundbreaking Clinical - openPR.com
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Up 1.9% – What’s Next? - Defense World
PharmaCyte Biotech (NASDAQ:PMCB) & LadRx (OTCMKTS:CYTR) Head to Head Analysis - Defense World
Malignant Ascites Treatment Market Detailed In New Research - openPR.com
PharmaCyte Biotech (OTCMKTS:PMCBD) Trading Up 1.7% – Still a Buy? - Defense World
PharmaCyte Biotech holds annual meeting, elects directors By Investing.com - Investing.com South Africa
PharmaCyte Biotech holds annual meeting, elects directors - Investing.com
PMCB stock touches 52-week low at $1.03 amid market challenges By Investing.com - Investing.com South Africa
PMCB stock touches 52-week low at $1.03 amid market challenges - Investing.com Australia
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 5.3% – Here’s What Happened - Defense World
Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Grows By 82.3% - Defense World
PMCB stock touches 52-week low at $1.38 amid market challenges - Investing.com India
PharmaCyte Biotech Inc. (PMCB) reports earnings - Quartz
PharmaCyte Biotech, Inc. SEC 10-Q Report - TradingView
PharmaCyte Biotech (OTCMKTS:PMCBD) Shares Down 1.1% – Here’s What Happened - Defense World
Contrasting PharmaCyte Biotech (OTCMKTS:PMCBD) & Tarsus Pharmaceuticals (NASDAQ:TARS) - Defense World
Advantage Continues Refreshment of its Board of Directors - BOE Report
PharmaCyte Biotech appoints new accounting firm By Investing.com - Investing.com South Africa
PharmaCyte Biotech appoints new accounting firm - Investing.com
Top Penny Stocks To Watch In February 2025 - Simply Wall St
PharmaCyte Biotech (OTCMKTS:PMCBD) and Tenaya Therapeutics (NASDAQ:TNYA) Head to Head Analysis - The AM Reporter
Head to Head Survey: Tenaya Therapeutics (NASDAQ:TNYA) and PharmaCyte Biotech (OTCMKTS:PMCBD) - Defense World
Pancreatic Cancer Precision Medicine Market Report, 2030 - Grand View Research
Malignant Ascites Treatment Market: Trends, Growth, - openPR
Pancreatic Cancer Treatment Market to Surge to USD 10.2 - GlobeNewswire
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Up 0.1% – What’s Next? - Defense World
Global Ascites Market Size and Trends, Forecast 2025-2035: Unlocking Key Insights for Strategic Growth – Custom Market Insights - BioSpace
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Shares Sold by Geode Capital Management LLC - Defense World
PharmaCyte Biotech (OTCMKTS:PMCBD) Trading 1.5% Higher – Time to Buy? - Defense World
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Up 1.5% – Still a Buy? - Defense World
Comparing Vaxcyte (NASDAQ:PCVX) & PharmaCyte Biotech (OTCMKTS:PMCBD) - Defense World
Financial Comparison: Coeptis Therapeutics (NASDAQ:COEP) & PharmaCyte Biotech (NASDAQ:PMCB) - Defense World
Pancreatic Cancer Treatment Market Size Worth USD 10.53 - GlobeNewswire
MyMD Pharmaceuticals Secures Strategic Investments - Business Wire
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease - Business Wire
Pharmacyte Biotech Inc (OTCMKTS:PMCB) Is At A Turning Point - Insider Financial
Femasys secures nearly $7M in funding from PharmaCyte - MassDevice
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology - Business Wire
PharmaCyte Biotech Announces Final Results of Tender Offer - Business Wire
Oblong Appoints Two New Directors to its Board - Business Wire
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share - Business Wire
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan - Business Wire
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value - Stock Titan
PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors - Seeking Alpha
PharmaCyte Biotech begins first phase of two-phase animal study to treat pancreatic cancer - Seeking Alpha
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study - Business Wire
PMCB stock gains on $10M share buyback program (NASDAQ:PMCB) - Seeking Alpha
1.45%
0.86%
자본화:
|
볼륨(24시간):